Aptevo Therapeutics Inc. - 8-K Filing

Aptevo Therapeutics reports Q3 2026 results highlighting a 79% remission rate for mipletamig in TP53-mutated AML and $4.5 million in new financing. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $APVO

Read the full article at SEC EDGAR

More Regulatory news